Safety, clinical efficacy, and patient-reported outcomes of a low-add intraocular lens in a large sample of patients from a real-world multicentre provider

Session Details

Session Title: Advanced Optic IOLs

Session Date/Time: Tuesday 17/09/2019 | 08:30-10:30

Paper Time: 08:30

Venue: Free Paper Forum: Podium 1

First Author: : D.Teenan UK

Co Author(s): :    S. Hannan   K. Hettinger                          

Abstract Details

Purpose:

To determine the safety profile and clinical efficacy of a premium intraocular lens (IOL) being implanted in a real world clinic environment.

Setting:

Treatments represent results from a real world, multicenter provider. Patients were implanted with the lens by one of eighteen surgeons at one of thirteen treatment centers across England, Scotland, and Ireland. Treatments occurred between January 2015 and December 2018.

Methods:

3362 consecutive patients implanted bilaterally with a Tecnis low add IOL. All patients completed a three month postoperative visit where clinical and patient reported parameters were captured. Adverse events and/or complications were recorded at any postoperative time period.

Results:

By 3 months, outcomes were efficacious with 88% achieving 6/6 Uncorrected Distance Visual Acuity (UCVA) and over 99% achieving UK diving standard. 92% reached N6 and 98% reached N8 near vision. 91% of patients reported being “satisfied” or “very satisfied” with outcome while 95% would have treatment again. Patients reported experiences with increased glare and haloes in 15%, and 18% of cases, respectively. The most common postoperative complications were Posterior Capsular Opacification (PCO), and dry eye, with prevalence rates of 4.8% and 3.5%, respectively. Less than 1% of patients experienced loss more than 2 lines Best Corrected Visual Acuity.

Conclusions:

The Tecnis low add IOL exhibits a low rate of complications in a large, multicentre, real word environment. It is a clinically effective treatment option with patients achieving significant visual improvements. Patients report high levels of satisfaction. The risk of increased symptoms for glare and/or halos may be warranted in a discussions of expectations.

Financial Disclosure:

is employed by a for profit company with an interest in the subject of the presentation